bioshares report, page-82

Very interesting posts. Some of the negativity around CZD and MC/ SP is surprising. I believe we are potentially 3-6 months off a significant re-rate. Management have said and repeated that approval should be followed by agreements and royalties. I have not read anything in posts that changes this view. If this does not eventuate then as shareholders we should be concerned about the message getting out and interest amongst wider medical community. We have been told that discussion have been held with interested parties. When money starts coming in CZD will increase in price. Until then it is another speculative biotech. All the speculative section of the market is struggling as investors are risk intolerant. With few examples very little increases on potential and if it does this is generally not sustained.
Keep the faith, change for change sake is not necessary. There needs to be benefits especially if existing time-lines are accurate.

Regard,
Bill